New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Check below for free stories on LPCN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
08:34 EDTLPCNLipocine announces Phase 3 study of LPCN 1021 met primary efficacy endpoint
Subscribe for More Information
05:22 EDTLPCNLipocine to host conference call
Subscribe for More Information
September 23, 2014
18:24 EDTLPCNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Bed Bath & Beyond (BBBY), up 7.4%. ALSO HIGHER: Lipocine (LPCN), up 15.9% after announcing webcast on Phase 3 study of LPCN 1021... ZS Pharma (ZSPH), up 5.1% after reporting positive top-line results from HARMONIZE, its second Phase 3 clinical trial of ZS-9. DOWN AFTER EARNINGS: AAR Corp. (AIR), down 3.5%. ALSO LOWER: Atossa Genetics (ATOS), down down 54.5% after ForeCYTE aspirator not awarded FDA clearance... Envision Healthcare (EVHC), down 2.2% after filing to sell 17.5M shares of common stock for holders.
16:52 EDTLPCNLipocine higher by 10% after announcing webcast on Phase 3 study of LPCN 1021
Subscribe for More Information
September 18, 2014
11:15 EDTLPCNRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
06:10 EDTLPCNFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
06:59 EDTLPCNLipocine trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use